Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Extension Study to Evaluate the Long-term Safety and Efficacy of Maralixibat in the Treatment of Subjects With Progressive Familial Intrahepatic Cholestasis (PFIC)

NCT04185363 is registered in ClinicalTrials.gov with Mirum Pharmaceuticals, Inc. as lead sponsor.

NCT NCT04185363
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04185363 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Extension Study to Evaluate the Long-term Safety and Efficacy of Maralixibat in the Treatment of Subjects With Progressive Familial Intrahepatic Cholestasis (PFIC)
Lead sponsor
Mirum Pharmaceuticals, Inc.
Phase
Phase 3
Overall status
Completed
Start date
January 8, 2020
Completion date
April 23, 2025
Enrollment
84 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

progressive familial intrahepatic cholestasis (pfic)